BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21747120)

  • 1. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
    Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
    Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
    Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
    Castro GN; Cayado-Gutiérrez N; Zoppino FC; Fanelli MA; Cuello-Carrión FD; Sottile M; Nadin SB; Ciocca DR
    Cell Stress Chaperones; 2015 Mar; 20(2):253-65. PubMed ID: 25155585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
    von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
    Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
    Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
    Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
    Shinsato Y; Furukawa T; Yunoue S; Yonezawa H; Minami K; Nishizawa Y; Ikeda R; Kawahara K; Yamamoto M; Hirano H; Tokimura H; Arita K
    Oncotarget; 2013 Dec; 4(12):2261-70. PubMed ID: 24259277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
    Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
    Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
    Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
    Ganesa S; Sule A; Sundaram RK; Bindra RS
    Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
    Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
    Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
    Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
    Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.
    D'Atri S; Graziani G; Lacal PM; Nisticò V; Gilberti S; Faraoni I; Watson AJ; Bonmassar E; Margison GP
    J Pharmacol Exp Ther; 2000 Aug; 294(2):664-71. PubMed ID: 10900246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
    Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
    Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
    Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
    Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
    Jiang G; Jiang AJ; Xin Y; Li LT; Cheng Q; Zheng JN
    Mol Biol Rep; 2014 Oct; 41(10):6659-65. PubMed ID: 24990698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
    Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
    Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.